Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.

X
Trial Profile

Effects of the Selective Mineralocorticoid Receptor Antagonist Eplerenone on Extracellular Adenosine Formation in Humans in Vivo.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Dec 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Eplerenone (Primary)
  • Indications Heart failure; Hypertension
  • Focus Pharmacodynamics
  • Acronyms eplerenone-01
  • Most Recent Events

    • 19 Dec 2022 This trial has been completed in Netherlands , according to European Clinical Trials Database record.(Global end date 23 Dec 2013 )
    • 30 Jan 2014 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
    • 31 Oct 2013 Planned End Date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top